OM:SOBIBiotechs
Assessing Swedish Orphan Biovitrum’s Valuation After Positive Phase 3 REDUCE 2 Gout Trial Results
Phase 3 REDUCE 2 results and why they matter for Swedish Orphan Biovitrum (OM:SOBI)
Swedish Orphan Biovitrum (OM:SOBI) has put pozdeutinurad (AR882) in the spotlight after reporting positive topline Phase 3 REDUCE 2 results in adults with gout, including patients not well controlled on existing therapies.
Both tested doses met the primary endpoint of achieving serum uric acid levels below 6 mg/dL at month 6 versus placebo, with an overall well tolerated safety profile. This raises fresh...